Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Inventory (2016 - 2025)

Veracyte (VCYT) has disclosed Inventory for 14 consecutive years, with $20.5 million as the latest value for Q4 2025.

  • Quarterly Inventory fell 5.54% to $20.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.5 million through Dec 2025, down 5.54% year-over-year, with the annual reading at $20.5 million for FY2025, 5.54% down from the prior year.
  • Inventory hit $20.5 million in Q4 2025 for Veracyte, up from $20.3 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $25.0 million in Q2 2025 to a low of $6.3 million in Q1 2021.
  • Historically, Inventory has averaged $15.8 million across 5 years, with a median of $15.2 million in 2022.
  • Biggest five-year swings in Inventory: skyrocketed 141.04% in 2021 and later fell 20.74% in 2023.
  • Year by year, Inventory stood at $11.2 million in 2021, then grew by 27.34% to $14.3 million in 2022, then increased by 12.83% to $16.1 million in 2023, then soared by 34.86% to $21.8 million in 2024, then dropped by 5.54% to $20.5 million in 2025.
  • Business Quant data shows Inventory for VCYT at $20.5 million in Q4 2025, $20.3 million in Q3 2025, and $25.0 million in Q2 2025.